CA9 and neoplasm: By enabling the specific recognition and elimination of hypoxic, CA IX-expressing tumor cells, these bi-specific adapters offer a novel immunotherapeutic avenue that could complement the effects of CA IX inhibitors and broaden the therapeutic landscape for solid tumors characterized by hypoxia and acidosis.